MacroGenics, Inc. (MGNX)
| Market Cap | 202.76M +153.1% |
| Revenue (ttm) | 149.50M -0.3% |
| Net Income | -74.62M |
| EPS | -1.18 |
| Shares Out | 63.56M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 589,316 |
| Open | 3.170 |
| Previous Close | 3.180 |
| Day's Range | 3.100 - 3.240 |
| 52-Week Range | 1.185 - 3.880 |
| Beta | 1.10 |
| Analysts | Buy |
| Price Target | 5.00 (+56.74%) |
| Earnings Date | May 12, 2026 |
About MGNX
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MG... [Read more]
Financial Performance
In 2025, MacroGenics's revenue was $149.50 million, a decrease of -0.31% compared to the previous year's $149.96 million. Losses were -$74.62 million, 11.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for MGNX stock is "Buy." The 12-month stock price target is $5.0, which is an increase of 56.74% from the latest price.
News
FDA Removes Partial Clinical Hold on MacroGenics' LINNET Study
• Plan to resume enrollment in clinical study of lorigerlimab in gynecologic cancers • On track to provide mid-2026 program update ROCKVILLE, MD, April 08, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc...
MacroGenics Transcript: Barclays 28th Annual Global Healthcare Conference
The session highlighted a robust oncology pipeline with three ADCs advancing, including MGC026 and MGC028, and a dual checkpoint inhibitor, lorigerlimab, facing a partial clinical hold. Strong partnerships and non-dilutive capital position the company for key 2026 milestones.
MacroGenics Transcript: The Citizens Life Sciences Conference 2026
Leadership sharpened focus on capital allocation and pipeline inflection points, with a strong cash runway through 2027. ADC and bispecific programs advance with promising safety and efficacy, while partnerships with Gilead, Incyte, and Sanofi offer substantial milestone and royalty potential.
MacroGenics Transcript: Leerink Global Healthcare Conference 2026
Management is prioritizing key pipeline assets and operational efficiency, with major clinical updates for lorigerlimab and ADC programs expected by mid-2026. Strong business development and a robust cash position support ongoing innovation and future milestones.
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures
ROCKVILLE, Md., March 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the tre...
MacroGenics Transcript: TD Cowen 46th Annual Health Care Conference
The session highlighted a robust pipeline of next-generation antibody therapeutics, strategic capital allocation, and strong partnerships driving non-dilutive funding. Key programs include ADCs targeting B7H3 and ADAM9, with a focus on innovation, risk management, and competitive positioning.
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD, Feb. 26, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer,...
MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial
FDA has placed partial clinical hold on LINNET study of lorigerlimab in gynecologic cancer FDA has placed partial clinical hold on LINNET study of lorigerlimab in gynecologic cancer
MacroGenics Transcript: Evercore ISI 8th Annual HealthCONx Conference
Pipeline focus shifted from prostate to gynecologic cancers for lorigerlimab, with the LINET study progressing and updates expected mid-next year. ADC programs using the Synaffix platform are advancing, with clinical data anticipated next year. Cash runway now extends into late 2027, supporting continued development.
MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference
ROCKVILLE, MD, Nov. 25, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer,...
MacroGenics Transcript: Stifel 2025 Healthcare Conference
A new CEO outlined six strategic imperatives, with progress on ADC and bispecific programs. The company discontinued its prostate cancer trial but continues the LINNET gynecological study, expecting a mid-2025 update. Expanded partnerships and recent milestones have extended the cash runway into late 2027.
MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress
ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer...
MacroGenics to Participate in the Stifel 2025 Healthcare Conference
ROCKVILLE, MD, Nov. 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer,...
MacroGenics Transcript: H.C. Wainwright 27th Annual Global Investment Conference
A diversified oncology pipeline is advancing, highlighted by a bispecific antibody with a 26% response rate in late-line prostate cancer and a robust ADC platform leveraging Synaffix technology. Strong financials and strategic partnerships support a cash runway through mid-2027.
MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference
ROCKVILLE, MD, Sept. 02, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer...
MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities
ROCKVILLE, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the trea...
MacroGenics Appoints Eric Risser as President and Chief Executive Officer
ROCKVILLE, MD, Aug. 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company developing innovative antibody-based therapeutics for the treatment of can...
MacroGenics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025
Significant financial strength was reinforced by a $70 million Sagard deal and a decade-long track record of non-dilutive capital. The pipeline features advanced bispecifics and ADCs, with Lorigerlimab and multiple ADCs progressing in clinical trials.
MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement
MacroGenics received $70 million upfront cash payment from Sagard Healthcare Partners (Sagard) MacroGenics' cash runway extended through first half of 2027 ROCKVILLE, MD, June 10, 2025 (GLOBE NEWSWIRE...
MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
ROCKVILLE, MD, June 03, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody...
MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results
ROCKVILLE, Md., May 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing inno...
MacroGenics Transcript: The Citizens JMP Life Sciences Conference 2025
The portfolio includes four clinical assets with diverse mechanisms, highlighted by lorigerlimab, a bispecific PD-1/CTLA-4 inhibitor in phase II for prostate cancer, and multiple ADC programs. Financial runway extends into 2026, with strong non-dilutive funding and key partnerships, including Gilead's option on a CD123 x CD3 bispecific.
MacroGenics Announces Date of First Quarter 2025 Financial Results
ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-ba...
MacroGenics to Participate in Upcoming Investor Conference
ROCKVILLE, MD, May 01, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-...
MacroGenics Earnings Call Transcript: Q4 2024
Revenue rose to $150M in 2024, driven by milestone payments, but net loss widened to $67M due to higher R&D and SG&A expenses. Key clinical milestones were achieved, including full enrollment in the LORIKEET trial and advancement of ADC programs, with a cash runway into H2 2026.